News

AbstractThe accumulation of amyloid fibrils has been identified in tissues outside the brain, yet little is understood about the formation of extracerebral…

July 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a…

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and…

AbstractBackgroundThe diagnosis of cardiac amyloidosis can be achieved noninvasively for transthyretin amyloid cardiomyopathy through nuclear scintigraphy with bone…

AbstractImmunoglobulin light chain amyloidosis (AL amyloidosis) is among the most common forms of systemic amyloidosis. Using electronic health records (EHR) data…

With targeted treatment using both medical therapy for transthyretin-associated cardiac amyloidosis (ATTR-CA) and valve replacement for aortic stenosis (AS),…

AbstractEpidermolysis bullosa (EB) is a rare, heterogeneous, hereditary, chronic skin disorder with severe cutaneous and extracutaneous involvement. With the…

 FRANKFORD (WPVI) -- Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being identified more and…

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix…

Immix Biopharma and its subsidiary Nexcella are currently conducting a phase 1b/2 clinical trial (NCT06097832; NEXICART-2) in the United States aimed at evaluating…